Cd. Saudek et al., IMPLANTABLE INSULIN PUMP VS MULTIPLE-DOSE INSULIN FOR NON-INSULIN-DEPENDENT DIABETES-MELLITUS - A RANDOMIZED CLINICAL-TRIAL, JAMA, the journal of the American Medical Association, 276(16), 1996, pp. 1322-1327
Objective.-To determine whether implantable insulin pump (IIP) therapy
and multiple daily insulin (MDI) injections could equally attain impr
oved blood glucose control, and to compare the 2 treatments with respe
ct to reducing daily blood glucose fluctuations: reducing serious hypo
glycemic insulin reactions, and improving patients' quality of life, D
esign.-Randomized clinical trial, Setting.-Seven Veterans Affairs medi
cal centers. Patients.-One hundred twenty-one male type II diabetic pa
tients between the ages of 40 and 69 years, receiving at least 1 injec
tion of insulin per day and having hemoglobin A(1c) (HbA(1c)) levels o
f 8% or above, Intervention.-Intensive therapy (IIP or MDI) for 1 year
, Main Outcome Measures.-Hemoglobin A(1c) and blood glucose levels, Re
sults.-Blood glucose levels declined to 7.96+/-1.08 mmol/L (143.4+/-19
.5 mg/dL) and 8.30+/-1.52 mmol/L (149.6+/-27.4 mg/dL) (mean +/- SD) fo
r IIP and MDI, respectively (P=.57), Hemoglobin A(1c) levels improved
in both groups (time effect P<.001), to means of 7.54%+/-0.83% (MDI) v
s 7.34%+/-0.79% (IIP), IIP reduced blood glucose fluctuations compared
with MDI (P<.001), and reduced the incidence of mild clinical hypogly
cemia by 68% (P<.001); IIP also eliminated the weight gain associated
with MDI therapy and yielded better overall quality-of-life (P=.03) an
d impact-of-disease subscale scores (P=.05), Adverse events included 2
5% of subjects with episodes of insulin underdelivery due to microprec
ipitates of insulin within the pump, Conclusions.-Intensive insulin th
erapy with IIP and MDI is effective in controlling non-insulin-depende
nt diabetes mellitus, IIP has significant advantages in reducing glyce
mic variability, clinical hypoglycemia, and weight gain, while improvi
ng aspects of quality of life.